RecruitingNCT04794296
Recommendations for the Treatment of Children With Acute Lymphoblastic Leukemia in the GFAOP
Sponsor
French Africa Pediatric Oncology Group
Enrollment
500 participants
Start Date
Nov 15, 2021
Study Type
OBSERVATIONAL
Conditions
Summary
The LALGFA2019 Recommendations redefine the standard risk criteria and propose to introduce anthracycline induction in so-called high-risk forms (LAL line T and LAL line B with leukocytosis greater than or equal to 50 G/L or in children less than 1 year of age or more than 10 years of age) as well as Endoxan and Methotrexate in high dose consolidation.
Eligibility
Max Age: 18 Years
Inclusion Criteria2
- Children 0 to 18 ALL first diagnosis No prior chemotherapy Cytology FAB L1 or L2
- \-
Exclusion Criteria1
- ALL L3 (Burkitt) ALL previously treated with chemotherapy Trisomy 21
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04794296